Skip to content

Total Equity at other companies

Tenet Healthcare logo
Tenet HealthcareTHC
$4.81B+15.1%
Merck & Co. logo
Merck & Co.MRK
$45.88B-5.1%
Insmed logo
InsmedINSM
$704.85M+611%
Ethos Technologies, Inc.
 logo
Ethos Technologies, Inc. LIFE
$57.93M-22.8%
LQD
Liquidia CorporationLQDA
$108.58M+118%
Johnson & Johnson logo
Johnson & JohnsonJNJ

Other financials

Income statement

See full
Revenue$781.5M-1.6%
Gross profit$648.1M-7.7%
Operating income$325.8M-14.9%
Net income$274.9M-14.7%
EPS (diluted)$5.82-12.2%

Balance sheet

See full
Cash & equivalents$1.3B-32.6%
Total debt$12.2M
Total assets$6.7B-13.3%

Cash flow

See full
Operating cash flow$463.3M+0.5%
CapEx$100.8M+34.6%
Free cash flow$362.5M-6.2%

Valuation

See full
Market cap$23B+84.1%
P/E17.9×+7.8×
P/S7.3×+3.2×

Profitability

See full
Gross margin86.6%-2.4pp
Operating margin45.3%-1.6pp
Net margin40.6%+0.2pp
FCF margin32.1%-5.6pp

Returns & leverage

See full
Return on equity20.3%+0.3pp
Debt / equity
Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is United Therapeutics's total equity?
United Therapeutics (UTHR) reported total equity of $5.9B in Q1 2026.
How has United Therapeutics's total equity changed year-over-year?
United Therapeutics's total equity decreased by 13.3% year-over-year, from $6.81B to $5.9B.
What is the long-term trend for United Therapeutics's total equity?
Over 5 years (2020 to 2025), United Therapeutics's total equity has grown at a 15.9% compound annual growth rate (CAGR), from $3.4B to $7.1B.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.